During the past decade, significant advances have been made in refinements for regenerative therapies following human spinal cord injury (SCI). Positive results have been achieved with different types of cells in various clinical studies of SCI. In this review, we summarize recently-completed clinical trials using cellmediated regenerative therapies for human SCI, together with ongoing trials using neural stem cells. Specifically, clinical studies published in Chinese journals are included. These studies show that current transplantation therapies are relatively safe, and have provided varying degrees of neurological recovery. However, many obstacles exist, hindering the introduction of a specifi c clinical therapy, including complications and their causes, selection of the target population, and optimization of transplantation material. Despite these and other challenges, with the collaboration of research groups and strong support from various organizations, cell-mediated regenerative therapies will open new perspectives for SCI treatment.
Introduction
A recent literature survey on spinal cord injury (SCI) shows an incidence ranging from 10.4 to 83 cases per million per year (average, 29.5) and a prevalence of 223-755 per million (average, 485) [1] . After SCI, the release of inhibitory molecules, insufficient expression of growth factors, and formation of glial scar at the injury site are negative local consequences that lead to the formation of an impermeable barrier that prevents axons from regenerating across the site of injury [2, 3] . Meanwhile, the capacity of endogenous stem-cell regeneration is limited in the adult central nervous system (CNS). Treatment of SCI poses great challenges to any standard regenerative therapy. Over the past 20 years, great emphasis has been placed on cell-mediated regenerative therapies, and exogenous cell transplantation is thought to be an important means of treating SCI ( Fig.   1 ). Neuronal function can be improved by applying different sources of cells to SCI, and these are not merely restricted to exogenous neural stem cells. Advances have been achieved albeit with considerable challenges. The safety of cell transplantation therapies via multiple routes has been widely confi rmed. However, their therapeutic effi cacy remains unsatisfactory, and the design of studies should be further considered (Fig. 2) . In this review, we summarize clinical studies with cell-mediated transplantation for SCI and strategies for further clinical applications. Also, we provide a practical overview of independent clinical studies published in Chinese journals.
Clinical Outcomes of Transplantation Therapy for SCI

Mesenchymal Stem Cell Trials
Mesenchymal stem cells (MSCs) can be obtained from bone marrow, fat, umbilical cord, periosteum, and placenta.
These tissues contain small numbers of adult stem cells, which can differentiate into various mesenchymal cells [4] . The leading role of MSCs is believed to be neuroprotective by secreting neurotrophic factors, rather than inducing neural regeneration by transdifferentiation into neurons or glia [5, 6] , while the exact mechanisms remain unknown [7] .
The immunosuppressive effects of MSCs are considered to be benevolent, particularly as they are thought to ease the characteristic symptoms of SCI by settling the infl ammatory response, which in due course reduces cavity formation and demyelination [8] . Under certain conditions, MSCs can be trans-differentiated into neurons and glial cells in vitro or ex vitro [9, 10] , but only an extremely small proportion differentiate and the function of the trans-differentiated cells is not convincing [11] (Table 1) . [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . A comparison between culture-expanded MSCs and human
Bone-marrow Mesenchymal Stem Cells
MCPs was made by transplanting them into rodent SCI models, but no differences were found [23] . To date, no clinical study has been reported.
Granulocyte-macrophage colony-stimulating factor (GM-CSF) has the ability to guide MCPs to the injured site and improve functional recovery in rodent SCI [24] . In some studies, MCPs have been transplanted in combination with GM-CSF administration, and GM-CSF was found to guide MCP migration to the lesion site, enhance the survival of transplanted cells, and activate the secretion of neurotrophic factors [12, 15, 20] . It is noteworthy that there is no detailed description of rehabilitation therapy in these reported MSCs trials other than "both the groups were given supervised physiotherapy, and it continued throughout the study period" [22] . Physical rehabilitation programs, which have proved their value in the functional recovery of SCI victims, should be described [31] . in July 2011 [34, 35] . In that study, cell grafts were directly 
Neural Stem Cell Trials
Trials of Other Cells
Schwann cells (SCs) are the main supportive glia in the peripheral nervous system. They were the fi rst cells to be used in SCI animals for the potential of promoting axon regeneration in the CNS [40] . Transplantation of SCs has been extensively investigated as a therapeutic intervention in preclinical SCI studies [41] . In December 2012, the autologous OECs obtained by biopsy 4-10 weeks before treatment [43] . Safety was demonstrated, but no significant functional benefit was found after transplantation. Lima et al. transplanted small pieces of olfactory mucosa into 20 patients with chronic traumatic SCI (AIS A-B) [44] , and found that the lesion site was fi lled in all patients, with no neoplastic growth or syringomyelia on MRI. Huang et al.
implanted fetal olfactory bulbs (3-4 months gestation) above and below the injured spinal cord site in 656 patients with chronic SCI [45] . The follow-up MRI did not reveal any new changes in the spinal cord parenchyma.
Macrophages can generate neurotrophic factors and block inhibitors in the peripheral nervous system. Knoller et al. initiated a phase I study with eight participants using direct injection of autologous macrophages into the spinal cord within 14 days after SCI [46] . Mild functional improvements without any critical adverse effects were found in three patients.
Current Status of Clinical Studies in China
Sixteen independent clinical trials have been reported in China, using BMMSCs, UC-MSCs, OECs, bone marrowderived NSCs, SCs and mononuclear cells [45, [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] . More than 1700 SCI patients have received cell-mediated transplantation therapy. However, almost all studies were reported in Chinese journals (Fig. 3) .
Wang et al. initiated the earliest trial in 420 chronic SCI patients (42 complete and 378 incomplete) in 2003 [50] , which was also the largest of the eight BMMSC studies [47] [48] [49] [50] [51] [52] [53] [54] .
The cells were transplanted into all patients through multiple routes including direct parenchymal, intrathecal, and [49] . The BMMSC group showed more motor function improvement than the UC-MSC group 3 months after transplantation.
Transplantation of autologous BMMSCs combined with peripheral nerve was initiated by Li et al. in 2003 [52] .
Autologous sural nerve was cut into cauda equina-like tissues, which were longitudinally transplanted into the spinal cord or intramedullary cysts. All of the 78 patients were discharged smoothly except for 1 with serious combined injury death with no autopsy. All 77 patients were improved, and no obvious adverse event was found.
Huang et al. initiated the fi rst and largest trial of OECs in 2001 [45] . They injected 1×10 6 cells directly into the injury site in each of the 656 chronic SCI patients. Two patients died of hypertension and cerebral hemorrhage, and severe pulmonary infection (1.5 and 1 month after operation).
There were no postmortem examinations. Cerebrospinal fl uid leakage occurred in 38 patients, and 8 suffered varying degrees of functional decline.
Cui et al. assessed the short-term curative effect and safety of autologous bone marrow mononuclear cell transplantation in 16 patients with SCI using intravenous or intrathecal delivery [60] . There was no significant functional improvement. The adverse effects, including headache, abdominal distension, and meningeal irritation, were found in the intrathecal group.
Challenges
Negative Outcomes of Clinical Trials
In the reported completed trials and those in progress, overall complications were rare, with no incidence of death due to transplantation therapy. The reports of specific complication details were variable throughout the published literature, and no adverse events were noted in those studies [14, 25, 62] .
The complications seem to be related to the aggressive procedure and application routes of cell-mediated therapy [14, 20] . For example, the most common complications of intrathecal injection, the most frequently used method of transplantation, are headache and neuropathic pain [21, 63] .
An additional concern by Kishk et al. is the development of neuropathic pain after this therapy, perhaps due to the recovery and formation of neuronal circuitry [21] .
Neuroplasticity is the foundation of recovery after SCI, but this contributes to neuropathology at the same time [64] .
The negative effects of neuroplasticity vary, depending on conditions. Treatment strategies aiming at increasing neurotrophins in the spinal cord powerfully promote axon growth. However, this effect appears to be most highly related to the negative aspects of neuroplasticity. Overall, these cell-mediated therapies are welltolerated. However, the incidence of adverse events has been shown to correlate with the utilization of independent auditors and predefined definitions of complications [65] [66] [67] [68] , neither of which was noted in any of the reported series.
As a result, it is suspected that the published studies under-report the true incidence of adverse events with these procedures. On the other hand, to mitigate the potential infl uence of these variables and to understand the incidence with which they occur, further basic investigations and randomized controlled studies are necessary.
Selection of Target Population
To ensure proper conduct of clinical trials in SCI, guidelines from the International Campaign for Cures of SCI Paralysis were published in 2007 [69] [70] [71] [72] . Nevertheless, the The stability of neurological function should be confi rmed by another 6-month observation. It might then be presumed that the SCI patient has entered the chronic stage while there is no confi rmed indication of dysfunctional change.
The cell transplantation therapies for SCI patients mainly focus on the cervical, thoracic, and cervicothoracic segments. The neurological recovery potential varies after an acute traumatic SCI; patients with cervical injuries tend to have a greater likelihood of motor improvement than those with thoracic injuries [62, 73] . Currently, there are still no persuasive data to compare the outcomes between cervical and thoracic SCI, but attention should be paid to this lacuna while establishing the inclusion criteria. evaluation, the patients without enough will to assume this responsibility should not be recruited into clinical trials [74] .
A chronic complete SCI population with stable dysfunction and better tolerance would be suitable for a phase I clinical trial. It is important to ensure that scientifi c knowledge, not unreasonable expectations of treatment, drives the study [75] .
In a phase II clinical trial, the group of subacute incomplete SCI participants is considered to be a better choice. The goal of this phase is to achieve the greatest benefi t with the least harm.
Optimization of Transplantation Material
Many 
Practical Issues
Several authors have stated that proof of safety and effi cacy through the use of large-animal models is indispensable in the development of stem-cell transplantation therapies, an opinion shared by others engaged in similar research [75] [76] [77] [78] [79] .
However, the requirement for large-animal models is unsettled, and some authors argue that rodent models provide sufficient preclinical evidence of treatment [80, 81] .
The fact that the first pluripotent stem-cell trial approved by the FDA was based on rodent models alone, suggests that this level of preclinical evidence is acceptable.
Several articles have highlighted the need for independent replication of promising discoveries before clinical research commences [76, 77] . However, lack of funding is a signifi cant obstacle. It is hoped that collaboration between government and industry will further such projects, in which partners share the risk, burden, and opportunities of transmuting cell-mediated therapy from bench to clinic.
Difficult regulatory procedures are frequently-cited obstacles to the manipulation of stem cells; procedures believed to be needlessly cumbersome inhibit research innovation and product development. In the fi rst pluripotent stem-cell trial for SCI, the company announced its discontinuance partly due to the cumbersome regulatory procedures [82] . Governing bodies should streamline procedures and make necessary adjustments to keep pace with scientifi c progress.
Perspectives
There are multiple challenges for the effi cient and routine 
